Genetic Technologies Ltd
NASDAQ:GENE
Genetic Technologies Ltd
Genetic Technologies Ltd. is a molecular diagnostics company that offers predictive testing and assessment tools to help physicians proactively manage women's health. The company is headquartered in Melbourne, Victoria. The firm is focused on the development and commercialization of genetic risk assessment technology. The firm is engaged in providing genomics-based tests in health, wellness and serious disease through its GeneType and EasyDNA brands. GTG is focused on developing an integrated predictive genetic testing and assessment tools enabling medical practitioners and their patients to proactively manage health. The Company’s geneType test is for breast cancer, colorectal cancer, ovarian cancer, prostate cancer, coronary artery disease and type two diabetes in a single test. The GeneType offers integrated risk testing for a range of serious conditions. GTG offers cancer predictive testing and assessment tools for physicians. Its Polygenic Risk Scores (PRS) platform offers integrated clinical and genetic risk delivering actionable outcomes from physicians and individuals.
Genetic Technologies Ltd. is a molecular diagnostics company that offers predictive testing and assessment tools to help physicians proactively manage women's health. The company is headquartered in Melbourne, Victoria. The firm is focused on the development and commercialization of genetic risk assessment technology. The firm is engaged in providing genomics-based tests in health, wellness and serious disease through its GeneType and EasyDNA brands. GTG is focused on developing an integrated predictive genetic testing and assessment tools enabling medical practitioners and their patients to proactively manage health. The Company’s geneType test is for breast cancer, colorectal cancer, ovarian cancer, prostate cancer, coronary artery disease and type two diabetes in a single test. The GeneType offers integrated risk testing for a range of serious conditions. GTG offers cancer predictive testing and assessment tools for physicians. Its Polygenic Risk Scores (PRS) platform offers integrated clinical and genetic risk delivering actionable outcomes from physicians and individuals.
This earnings call has not been analyzed yet.
If you’d like us to analyze this earnings call, click the "Request Earnings Call Analysis" button below.
